This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Cerebrovascular Disease  • Multiple Sclerosis/ Demyelinating Disease  • Neuropathology  • Statistics and Research Methods  • Randomized Controlled Trial  • Alert me on articles by topic

Leaps and Bounds

Arch Neurol. 2002;59:689-691.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

NEUROLOGY HAS emerged from an immature era of therapeutic nihilism to witness incremental and tangible advances in the treatment of a variety of disorders. These gains have emanated largely from sound scientific underpinnings and form the basis for the rational selection and objective testing of experimental interventions. Neurologic therapeutics is finally reaping benefits from the convergence of laboratory-based investigations and randomized clinical trials.

A DECADE OF INCREMENTAL GAINS

In the past decade, treatments have emerged for several neuromuscular diseases. Several seemingly esoteric muscle disorders are now known to represent functional disruption of the ion channels in skeletal muscle, leading to more targeted and effective suppression of their paroxysmal manifestations.¹ Even the inexorable progression of amyotrophic lateral sclerosis, to death or tracheostomy, has shown evidence of slowing, albeit marginally, with riluzole treatment.² Migraine therapy has been transformed by a variety of specific serotonin agonists and the emerging insight that cortical spreading depression is involved in the . . . [Full Text of this Article]

QUANTUM LEAPS?

THE BOUNDS OF PROGRESS

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(5):878-880.
FULL TEXT